This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.

This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.

An isolated antibody, consisting of an anti-glutathionylated eNOS antibody, wherein the anti-glutathionylated eNOS antibody has been generated against an immunogen consisting of a peptide that includes glutathione; a first linker; an eNOS peptide; a second linker; and a T-cell epitope; and wherein the anti-glutathionylated eNOS antibody is adapted to recognize redox modulated eNOS proteins.

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

This document provides methods and materials related to CDV H and/or CDV F polypeptides. For example, CDV H polypeptides, CDV F polypeptides, recombinant viruses (e.g., vesicular stomatitis viruses (VSVs)) containing CDV H polypeptides and/or CDV F polypeptides, nucleic acid molecules encoding a CDV H polypeptide and/or CDV F polypeptide, methods for making recombinant viruses (e.g., VSVs) containing CDV H polypeptides and/or CDV F polypeptides, and methods for using recombinant viruses (e.g., VSVs) containing CDV H polypeptides and/or CDV F polypeptides to treat cancer or infectious diseases are provided.

Disclosed herein are methods for detecting and producing PoMV. Further, disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing PoMV. The compositions and methods include immunogenic portions of PoMV including entry proteins. In at least particular cases, a mutated version of a portion of the PoMV is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.